Free Trial

Immatics (IMTX) Competitors

Immatics logo
$5.64 +0.05 (+0.89%)
As of 07/3/2025 03:07 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

IMTX vs. HCM, OGN, AMRX, MIRM, XENE, BHC, IBRX, GMTX, ARWR, and APLS

Should you be buying Immatics stock or one of its competitors? The main competitors of Immatics include HUTCHMED (HCM), Organon & Co. (OGN), Amneal Pharmaceuticals (AMRX), Mirum Pharmaceuticals (MIRM), Xenon Pharmaceuticals (XENE), Bausch Health Cos (BHC), ImmunityBio (IBRX), Gemini Therapeutics (GMTX), Arrowhead Pharmaceuticals (ARWR), and Apellis Pharmaceuticals (APLS). These companies are all part of the "pharmaceutical products" industry.

Immatics vs. Its Competitors

Immatics (NASDAQ:IMTX) and HUTCHMED (NASDAQ:HCM) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

HUTCHMED has a net margin of 0.00% compared to Immatics' net margin of -14.73%. HUTCHMED's return on equity of 0.00% beat Immatics' return on equity.

Company Net Margins Return on Equity Return on Assets
Immatics-14.73% -4.52% -3.34%
HUTCHMED N/A N/A N/A

In the previous week, HUTCHMED had 3 more articles in the media than Immatics. MarketBeat recorded 3 mentions for HUTCHMED and 0 mentions for Immatics. Immatics' average media sentiment score of 0.00 equaled HUTCHMED'saverage media sentiment score.

Company Overall Sentiment
Immatics Neutral
HUTCHMED Neutral

Immatics currently has a consensus target price of $14.67, suggesting a potential upside of 160.05%. HUTCHMED has a consensus target price of $19.00, suggesting a potential upside of 19.54%. Given Immatics' stronger consensus rating and higher probable upside, equities analysts clearly believe Immatics is more favorable than HUTCHMED.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immatics
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.20
HUTCHMED
0 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

HUTCHMED has higher revenue and earnings than Immatics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Immatics$168.65M4.06$16.47M-$0.17-33.18
HUTCHMED$630.20M4.40$37.73MN/AN/A

64.4% of Immatics shares are held by institutional investors. Comparatively, 8.8% of HUTCHMED shares are held by institutional investors. 3.3% of Immatics shares are held by company insiders. Comparatively, 3.6% of HUTCHMED shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Immatics has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500.

Summary

HUTCHMED beats Immatics on 8 of the 14 factors compared between the two stocks.

Get Immatics News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMTX vs. The Competition

MetricImmaticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$694.05M$2.89B$5.56B$9.04B
Dividend YieldN/A2.44%5.24%4.01%
P/E Ratio-33.1721.7127.6620.25
Price / Sales4.06281.81415.41118.18
Price / Cash23.3742.7336.8958.07
Price / Book1.107.518.035.67
Net Income$16.47M-$55.14M$3.18B$249.21M
7 Day Performance3.87%4.61%2.93%3.27%
1 Month Performance-2.42%4.72%3.75%5.55%
1 Year Performance-51.96%5.92%35.20%21.08%

Immatics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMTX
Immatics
2.4535 of 5 stars
$5.64
+0.9%
$14.67
+160.0%
-52.3%$694.05M$168.65M-33.17260Positive News
HCM
HUTCHMED
1.3561 of 5 stars
$15.05
-0.3%
$19.00
+26.2%
-9.3%$2.63B$630.20M0.001,811
OGN
Organon & Co.
4.8953 of 5 stars
$9.68
-1.8%
$18.00
+86.0%
-50.4%$2.56B$6.40B3.364,000Trending News
AMRX
Amneal Pharmaceuticals
3.2096 of 5 stars
$8.09
-0.5%
$11.60
+43.4%
+26.8%$2.55B$2.79B-202.208,100High Trading Volume
MIRM
Mirum Pharmaceuticals
3.7333 of 5 stars
$50.89
-0.4%
$65.50
+28.7%
+47.4%$2.53B$336.89M-31.61140News Coverage
XENE
Xenon Pharmaceuticals
2.929 of 5 stars
$31.30
-3.4%
$54.82
+75.1%
-3.9%$2.49B$9.43M-9.69210
BHC
Bausch Health Cos
3.1195 of 5 stars
$6.68
+3.4%
$7.42
+11.0%
-2.8%$2.39B$9.63B-60.7320,700
IBRX
ImmunityBio
1.8594 of 5 stars
$2.64
-2.2%
$12.25
+364.0%
-57.0%$2.38B$14.74M-4.55590Negative News
Gap Up
GMTX
Gemini Therapeutics
N/A$54.50
+0.7%
N/A+23.2%$2.36BN/A-54.5030High Trading Volume
ARWR
Arrowhead Pharmaceuticals
3.9458 of 5 stars
$15.80
-1.7%
$43.71
+176.7%
-33.1%$2.22B$3.55M-11.29400
APLS
Apellis Pharmaceuticals
4.4296 of 5 stars
$17.31
-0.7%
$40.05
+131.4%
-49.2%$2.19B$781.37M-9.67770Trending News
Analyst Forecast
Analyst Revision

Related Companies and Tools


This page (NASDAQ:IMTX) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners